Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 3, 2020

Trevena partners with Imperial College London to assess TRV027

Biopharmaceutical company Trevena has partnered with Imperial College London to assess TRV027 in a Phase Ib clinical study for the treatment of acute lung injury related to acute respiratory distress syndrome (ARDS) in Covid-19 patients.

Biopharmaceutical company Trevena has partnered with Imperial College London to assess TRV027 in a Phase Ib clinical study for the treatment of acute lung injury related to acute respiratory distress syndrome (ARDS) in Covid-19 patients.

In Covid-19 infection, the virus attaches to and removes the ACE2 protein in the lungs, resulting in elevated angiotensin II levels. This causes overactivation of the AT1 receptor, which leads to downstream acute lung injury.

TRV027 is a selective AT1 receptor agonist. It is expected to counteract overactivation of the AT1 receptor caused by SARS-CoV-2, and also promote the repair of lung tissue.

The drug candidate was previously evaluated in a Phase IIb trial for acute heart failure.

Trevena president and CEO Carrie Bourdow said: “TRV027 may offer a new and innovative approach to treating acute lung injury, which poses a grave threat to patients’ lives.”

The randomised, double-blind, placebo-controlled Phase Ib trial will evaluate the drug candidate in about 60 hospitalised, non-ventilated patients aged 65 or older with confirmed or suspected Covid-19 infection.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

During the proof-of-concept study, TRV027 will be assessed for its ability to modulate pathways involved in Covid-19 pathology.

The primary endpoint of the trial is a coagulation cascade biomarker, which indicates the effect of the drug candidate on adverse health outcomes related to increased mortality in Covid-19 patients.

Imperial College London will sponsor and fund the trial while the British Heart Foundation Centre for Research Excellence Award offer additional support.

Last month, Imperial College London secured £22.5m from the UK Government to speed-up the development of a potential Covid-19 vaccine.

Since February, researchers at Imperial have been studying a self-amplifying RNA vaccine candidate in animals, with plans for human clinical trials.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU